SynCardia Systems, LLC: Company Profile

Background

SynCardia Systems, LLC, headquartered in Tucson, Arizona, is the manufacturer of the world's first and only FDA and Health Canada-approved Total Artificial Heart (TAH). Founded in 2001 by Dr. Jack G. Copeland, Dr. Marvin J. Slepian, and Richard G. Smith, SynCardia has been dedicated to providing life-saving solutions for patients with end-stage biventricular heart failure. The company's mission is to pioneer the future of heart replacement by offering the SynCardia Total Artificial Heart as a bridge to transplant and developing next-generation systems as alternatives to traditional heart transplantation.

Key Strategic Focus

SynCardia's strategic focus centers on the development and commercialization of the SynCardia Total Artificial Heart, a device designed to replace both ventricles and four heart valves in patients with end-stage biventricular heart failure. This device serves as a bridge to heart transplantation, providing patients with a life-saving solution while awaiting a donor heart. The company is also committed to advancing next-generation technologies, including the development of a fully implantable Total Artificial Heart system, known as "The Emperor," aimed at enhancing patient mobility and quality of life.

Financials and Funding

SynCardia has secured substantial funding over the years to support its innovative endeavors. In 2010, the company raised $8 million in venture capital from Iron Gate Investments and other investors. Subsequent funding rounds include:

May 2004: $3.7 million in Series B funding.

June 2009: $10.3 million in Series D funding led by Highway 12 Ventures.

March 2013: $19 million in debt and venture equity funding from Athyrium Opportunities Fund.

December 2013: $14 million in venture equity funding from Wedbush PacGrow Life Sciences.

In September 2016, SynCardia was acquired by Versa Capital Management, LLC, and later by Picard Medical in September 2021, providing additional financial and operational resources to advance its mission.

Pipeline Development

SynCardia's primary pipeline candidate is the SynCardia Total Artificial Heart, which has been in clinical use for over 35 years. The device is approved by the FDA and Health Canada and has been successfully used in over 2,000 patients worldwide. The company is also developing "The Emperor," a fully implantable Total Artificial Heart system aimed at enhancing patient mobility and quality of life. In February 2026, SynCardia presented a webinar on "The Emperor," discussing early preclinical insights and engineering innovations shaping the development of this next-generation platform.

Technological Platform and Innovation

SynCardia's technological platform is centered around the Total Artificial Heart, a device that replaces both ventricles and four heart valves in patients with end-stage biventricular heart failure. The company offers two sizes of the TAH to accommodate diverse patient physiologies:

70cc TAH: Designed for adult patients.

50cc TAH: Intended for pediatric and smaller adult patients.

The TAH is powered by external pneumatic drivers, including the Companion 2 Hospital Driver and the Freedom Portable Driver, which allow patients to be discharged from the hospital and maintain a quality of life while awaiting a heart transplant. SynCardia is also developing "The Emperor," a fully implantable Total Artificial Heart system aimed at eliminating the need for external drivers and enhancing patient mobility.

Leadership Team

SynCardia's leadership team includes:

Patrick NJ Schnegelsberg: Chief Executive Officer.

Bernard Skaggs: Chief Financial Officer.

Matthew Schuster: Chief Operating Officer.

Frank Tinker: Chief Technology Officer.

Elizabeth Oei: Director - Global Distribution & Clinical Education.

These leaders bring extensive experience in medical device development, operations, and global distribution, driving SynCardia's mission to advance heart replacement technologies.

Competitor Profile

Market Insights and Dynamics

The market for artificial hearts and ventricular assist devices is growing, driven by the increasing prevalence of heart failure and the need for alternative treatments to heart transplantation. SynCardia's Total Artificial Heart is the only FDA and Health Canada-approved device in this category, positioning the company as a leader in this specialized market.

Competitor Analysis

SynCardia's primary competitors include:

HeartWare International Inc.: A global medical device company specializing in implantable heart pumps for the treatment of advanced heart failure.

Abiomed Inc.: A medical device company that develops and manufactures heart pump technologies, including the Impella heart pump.

TransMedics Inc.: A company that develops and commercializes organ transplant technologies, including the Organ Care System for heart transplantation.

These companies offer alternative solutions for heart failure patients, but SynCardia's Total Artificial Heart remains unique in its ability to replace both ventricles and four heart valves, providing a comprehensive solution for end-stage biventricular heart failure.

Strategic Collaborations and Partnerships

SynCardia has engaged in strategic collaborations to advance its technology:

Hydrix: In February 2026, SynCardia announced a development collaboration with Hydrix to advance "The Emperor," a fully implantable Total Artificial Heart system. Hydrix's expertise in complex cardiovascular technologies supports SynCardia's objective of developing solutions for patients with advanced heart failure.

Operational Insights

SynCardia's operational strategy focuses on maintaining its leadership in the Total Artificial Heart market by:

Continuing to innovate and develop next-generation heart replacement technologies.

Expanding global distribution through strategic partnerships and collaborations.

Enhancing patient outcomes by providing comprehensive support and education to healthcare providers and patients.

Strategic Opportunities and Future Directions

SynCardia is well-positioned to capitalize on several strategic opportunities:

Advancing "The Emperor" System: Developing a fully implantable Total Artificial Heart system to eliminate the need for external drivers and improve patient mobility.

Expanding Global Reach: Increasing the availability of the SynCardia Total Artificial Heart in international markets through strategic partnerships and regulatory approvals.

Enhancing Clinical Outcomes: Conducting further clinical studies to demonstrate the long-term efficacy and safety of the Total Artificial Heart, supporting its use as a destination therapy for patients ineligible for heart transplantation.